News

GlobalData on MSN1d
Supernus makes depression drug play with $795m Sage buyout
After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...
Sage, following Setbacks, to sell to Supernus for $561M
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...
Fierce Pharma1d
Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...
BioSpace1d
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...
pharmaphorum1d
After rebuffing Biogen, Sage pairs off with Supernus
The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...
TMCnet1d
SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sage Therapeutics, Inc. (NASDAQ: SAGE) to Supernus Pharmaceuticals, Inc. is fair to Sage shareholders. Under the ...